ImmunoCellular (IMUC) SPA from FDA 'Significant', Roth Capital Says

Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $3 price target on ImmunoCellular Therapeutics (NYSE: IMUC) after the company announced the receipt of a Special Protocol Assessment (SPA) from the FDA for the pending start of the ICT-107 study in front-line glioblastoma.

"We believe this is a significant achievement for IMUC, which has been quite engaged with the regulatory authorities following the Phase II data showing the survival benefit in HLA-A2 patients," Pantginis said.

For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.

Shares of ImmunoCellular Therapeutics closed at $0.44 yesterday.

You May Also Be Interested In

• Qualcomm (QCOM) PT Raised to $300 at Benchmark
• BTIG Downgrades Apollo Commercial Real Estate Finance (ARI) to Neutral
• Benchmark Starts Prosperity Bancshares (PB) at Hold